Description

Overview

Orforglipron (development code LY3502970) is a small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor. Most compounds that activate the GLP-1 receptor are peptides, which are broken down in the digestive tract. Orforglipron is a non-peptide molecule designed to activate the same receptor while remaining stable in the digestive tract, which makes it an important compound in research comparing oral and peptide-based incretin pharmacology.

Peptide Sciences Bio supplies orforglipron as 90 capsules of 12mg each (1,080mg total) for preclinical laboratory investigation. Every batch is supported by independent analytical testing and a published Certificate of Analysis.

Product Specifications

ProductOrforglipron (LY3502970)
Quantity12mg per capsule; 90 capsules (1,080mg total)
ClassNon-peptide small-molecule GLP-1 receptor agonist
Molecular formulaC48H48F2N10O5
Molecular weight883.9 g/mol
CAS number2212020-52-3
FormCapsules
DocumentationBatch-specific Certificate of Analysis

Background: The Incretin System

Incretins are gut hormones released after nutrient intake. The two best characterized are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both act on pancreatic beta cells to support glucose-dependent insulin secretion, and their receptors are also found in the brain, gastrointestinal tract and adipose tissue. Native GLP-1 and GIP are broken down within minutes by the enzyme DPP-4, so research compounds in this class are engineered for much longer stability, typically through amino acid substitutions and fatty acid chains that bind to serum albumin.

Small Molecule vs. Peptide Agonists

Peptide GLP-1 agonists bind the receptor across a large surface, mimicking the natural hormone. Orforglipron is much smaller and binds a different pocket in the receptor. Structural studies show it activates the receptor through a distinct binding mode, which has made it a useful tool for understanding how non-peptide molecules can activate class B G protein-coupled receptors.

Because it is not a peptide, orforglipron is not degraded by digestive proteases and does not require absorption enhancers, unlike oral peptide formulations.

Mechanisms Studied

  • GLP-1 receptor activation: partial and biased agonism, with preferential cAMP signaling over beta-arrestin recruitment.
  • Glucose-dependent insulin secretion: beta-cell responses in metabolic models.
  • Gastric emptying and appetite signaling: classic GLP-1 receptor effects examined for a small-molecule agonist.
  • Oral pharmacokinetics: absorption and exposure without food or water restrictions.

Areas of Study

  • Oral incretin pharmacology
  • GLP-1 receptor structural biology
  • Glucose metabolism research
  • Small-molecule versus peptide agonist comparisons

These findings come from laboratory, animal and clinical research on orforglipron as a pharmaceutical ingredient. They do not apply to this research-grade material, which is not an approved drug product and is not intended for human use.

Related Research Peptides

Quality & Testing

Every batch of orforglipron is independently tested for identity and purity before release. Testing includes high-performance liquid chromatography (HPLC) to confirm purity and mass spectrometry (MS) to confirm molecular identity. The batch-specific Certificate of Analysis is available on this page and in our COA library, so researchers can verify the exact material they receive.

Storage & Handling

  • Store orforglipron capsules in a cool, dry place, ideally at 2–8°C, in the original sealed container.
  • Keep the container tightly closed and protected from light and humidity.
  • Avoid repeated temperature cycling, which can introduce moisture.
  • Handle using standard laboratory practices and appropriate protective equipment.

Frequently Asked Questions

What is orforglipron?

Orforglipron is a small-molecule, non-peptide agonist of the GLP-1 receptor, studied in research on oral incretin pharmacology and receptor structural biology.

Is orforglipron a peptide?

No. Orforglipron is a small molecule. It activates the GLP-1 receptor, the same target as peptide agonists such as semaglutide, but through a different binding mode.

Is this the same as the prescription medicine?

No. orforglipron is the active ingredient in FDA-approved prescription medicines, but this product is not one of them. Peptide Sciences Bio’s orforglipron is a research-grade material that is not approved for human or veterinary use and is sold strictly for laboratory research.

How should orforglipron be stored?

Store orforglipron capsules in a cool, dry place, ideally at 2–8°C, in the original sealed container, protected from light and humidity.

What does the Certificate of Analysis include?

Each COA reports the batch number, HPLC purity results and mass spectrometry confirmation of molecular identity for that specific batch.

Research Use Only

This product is intended solely for in-vitro research and laboratory experimentation by qualified professionals. It is not a drug, food, supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis, treatment or prevention of any condition. Purchase is restricted to buyers who agree to our Terms of Sale.

Additional information​

Product FormCapsules

Orforglipron 12mg/Capsule (90 Capsules)

Original price was: $415.00.Current price is: $370.00.

Orforglipron 12mg/Capsule (90 capsules, 1,080mg total) is a small-molecule, non-peptide GLP-1 receptor agonist. Unlike peptide GLP-1 agonists, it is chemically stable in the digestive tract, making it a key compound in research on oral incretin pharmacology. Batch-specific COA available. For laboratory research use only.

Shipping & 30 Days Return

Worldwide tracked delivery. Dispatched within 24 hours of order confirmation.

Not satisfied? Return any item within 10 days for a full refund, no questions asked.